RecruitingNot ApplicableNCT06079294

Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism

Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism : a Prospective FDG PET Study

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

56 participants

Start Date

May 31, 2024

Study Type

INTERVENTIONAL

Conditions

Autoimmune Encephalitis

Summary

Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10 days of treatment initiation.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying FDG PET for people with autoimmune encephalitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.